What is the preferred angiotensin receptor blocker (ARB) for adults, and what are the recommended starting doses and monitoring guidelines?

Best ARB for Adults

For most adults with hypertension, candesartan (target 32 mg daily) or valsartan (target 160 mg twice daily) are the preferred ARBs based on the strongest guideline evidence, with olmesartan and telmisartan as excellent alternatives when considering 24-hour blood pressure control and tolerability. 1

Clinical Context Determines the Optimal Choice

For Heart Failure with Reduced Ejection Fraction (HFrEF)

Candesartan and valsartan are the only ARBs with Class I, Level A evidence for reducing mortality and hospitalization in HFrEF. 2

• Candesartan: Start 4-8 mg once daily, titrate to target 32 mg daily
• Valsartan: Start 20-40 mg twice daily, titrate to target 160 mg twice daily (320 mg total daily)
• Losartan: While listed in guidelines, it requires 100 mg daily (FDA max) versus the guideline-recommended 150 mg target, making it less optimal 2

Critical point: Aim for at least 50% of target dose to achieve mortality benefit. Studies show a dose-response relationship—treating below target doses results in worse clinical outcomes. 2

For Hypertension Without Heart Failure

All first-line ARBs are acceptable, but newer ARBs (olmesartan, telmisartan, candesartan) demonstrate superior 24-hour blood pressure control compared to older agents (losartan, valsartan). 1, 3, 4

Recommended starting doses and targets:

• Candesartan: Start 8-16 mg daily → target 32 mg daily 1
• Olmesartan: Start 20 mg daily → target 40 mg daily 1
• Telmisartan: Start 40 mg daily → target 80 mg daily 1
• Irbesartan: Start 150 mg daily → target 300 mg daily 1
• Valsartan: Start 80-160 mg daily → target 320 mg daily 1
• Losartan: Start 25-50 mg daily → target 100 mg daily 1
• Azilsartan: Start 40 mg daily → target 80 mg daily 1

For Diabetes with Chronic Kidney Disease

Any ARB is acceptable when eGFR <60 mL/min/1.73 m² or albuminuria ≥30 mg/g, but ACE inhibitors remain first-line unless contraindicated. 5, 3

• ARBs and ACE inhibitors have equivalent renoprotective effects
• Never combine an ARB with an ACE inhibitor—this increases hyperkalemia and acute kidney injury risk without additional benefit 1, 3
• Start at lower doses in CKD and monitor potassium and creatinine within 1-2 weeks

Key Evidence Distinguishing ARBs

Blood Pressure Efficacy

Losartan is consistently inferior to other ARBs for blood pressure reduction. A comprehensive meta-analysis of 24-hour ambulatory blood pressure monitoring showed losartan 50 mg lowered BP 2.5/1.8 mmHg less than other ARBs at equivalent doses, and losartan 100 mg lowered BP 3.9/2.2 mmHg less than other ARBs at maximum doses. 6

Olmesartan and telmisartan demonstrate the best 24-hour blood pressure control and highest control rates in clinical trials. 7, 8 Network meta-analysis shows olmesartan ranks highest for office BP reduction (91.4% for systolic, 87.2% for diastolic), while candesartan ranks highest for 24-hour ambulatory systolic BP (95.4%). 8

Cardiovascular Outcomes

For cardiovascular protection beyond blood pressure lowering, telmisartan has unique evidence from ONTARGET showing equivalence to ramipril (an ACE inhibitor) in preventing cardiovascular events in high-risk patients, with better tolerability. 9 However, this does not establish superiority over other ARBs—it simply confirms ARBs as a class are equivalent to ACE inhibitors for cardiovascular protection.

Safety and Tolerability

All ARBs have similar safety profiles with placebo-like tolerability. 1 Olmesartan ranks highest for safety in network meta-analysis (70.8%), with olmesartan and telmisartan associated with fewer adverse events than losartan. 8

Practical Prescribing Algorithm

1. Heart failure (LVEF ≤40%): Use candesartan or valsartan (proven mortality benefit)
2. Hypertension requiring 24-hour control: Prefer olmesartan, telmisartan, or candesartan
3. Cost-sensitive situations: Losartan or valsartan (generic availability), but recognize losartan's inferior BP-lowering efficacy
4. Diabetes with CKD: Any ARB acceptable; start low, titrate slowly, monitor electrolytes
5. Prior angioedema with ACE inhibitor: Wait 6 weeks after ACE inhibitor discontinuation before starting ARB; extreme caution required 1, 10

Monitoring Requirements

• Baseline: Potassium, creatinine, blood pressure
• 1-2 weeks after initiation or dose change: Repeat potassium and creatinine
• Avoid if: Bilateral renal artery stenosis, pregnancy, history of angioedema with ARBs
• Watch for hyperkalemia risk: CKD, diabetes, concurrent potassium-sparing diuretics, NSAIDs, potassium supplements 1

Critical Pitfalls to Avoid

Do not undertitrate. The dose-response curve for ARBs is shallow—uptitration provides marginal additional BP reduction 6—but achieving at least 50% of target dose is essential for cardiovascular benefit in heart failure. 2

Do not combine ARB + ACE inhibitor. This combination increases adverse events (hyperkalemia, acute kidney injury, hypotension) without improving outcomes. 1, 10, 3, 4

Do not assume all ARBs are equivalent. While the class effect is similar, losartan consistently underperforms for BP reduction, and only candesartan and valsartan have mortality data in heart failure. 2, 6